Get the Stockscreener App
14.03
69.85%
5.77
After Hours:
14.37
0.34
+2.42%
Terns Pharmaceuticals Inc stock is traded at $14.03, with a volume of 33.92M.
It is up +69.85% in the last 24 hours and up +70.47% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$8.26
Open:
$14.05
24h Volume:
33.92M
Relative Volume:
18.83
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-10.63
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+74.07%
1M Performance:
+70.47%
6M Performance:
+300.86%
1Y Performance:
+102.16%
1-Day Range:
$12.77
$16.27
1-Week Range:
$7.775
$16.27
52-Week Range:
$1.865
$16.27
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
14.03 | 722.84M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Oppenheimer raises Terns Pharmaceuticals stock price target to $24 on promising leukemia drug data - Investing.com Nigeria
Pharmaceutical Stocks To Add to Your WatchlistNovember 3rd - MarketBeat
Biotech Deals And Breakthroughs Spark Heavy Trading Across Markets - Finimize
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades - Benzinga
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform - Investing.com
Terns Pharmaceuticals (TERN) Upgraded After Promising Clinical T - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy By Investing.com - Investing.com Philippines
Terns Pharmaceuticals (TERN) Presents Promising Data from CARDINAL Trial - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy - Investing.com
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting - The Manila Times
Terns Pharmaceuticals Announces Positive Data from CARDINAL Trial - TradingView
Combining price and volume data for Terns Pharmaceuticals Inc.Earnings Summary Report & Real-Time Buy Signal Alerts - newser.com
Will Terns Pharmaceuticals Inc. stock recover after recent dropPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Applying Wyckoff theory to Terns Pharmaceuticals Inc. stockMarket Trend Review & High Conviction Buy Zone Picks - newser.com
Price momentum metrics for Terns Pharmaceuticals Inc. explainedGap Up & High Yield Stock Recommendations - newser.com
Should you hold or exit Terns Pharmaceuticals Inc. nowTrade Ideas & Intraday High Probability Setup Alerts - newser.com
Real time breakdown of Terns Pharmaceuticals Inc. stock performanceQuarterly Performance Summary & Target Return Focused Stock Picks - newser.com
How hedge fund analytics apply to Terns Pharmaceuticals Inc. stockWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Is Terns Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
How Terns Pharmaceuticals Inc. stock reacts to Fed rate cutsMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Advanced analytics toolkit walkthrough for Terns Pharmaceuticals Inc.Portfolio Value Report & Real-Time Market Trend Scan - newser.com
What Wall Street predicts for Terns Pharmaceuticals Inc. stock priceM&A Rumor & Long-Term Safe Return Strategies - newser.com
What does recent volatility data suggest for Terns Pharmaceuticals Inc.Entry Point & Step-by-Step Swing Trade Plans - newser.com
Terns Pharmaceuticals Inc Stock Analysis and ForecastSwing Trading Watchlist & Today’s Picks, Tomorrow’s Winners - earlytimes.in
How sentiment analysis helps forecast Terns Pharmaceuticals Inc.Market Performance Recap & High Accuracy Swing Entry Alerts - newser.com
Sector ETF performance correlation with Terns Pharmaceuticals Inc.2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
Terns Pharmaceuticals (TERN) Price Target Decreased by 11.67% to 16.14 - MSN
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):